M. Mastrangelo, M.D.; R. S. Bornstein, M.D.; H. Sulit, M.D.; D. Chee, Ph.D.; J. VV. Yarbro, M.D., F.A.C.P.; R. T. Prehn, M.D.
This content is PDF only. Please click on the PDF icon to access.
Extensive investigation of the immunology of animal and human neoplasia suggests that host immunity may be a significant factor in host resistance to cancer. Furthermore, this immunological response may be capable of augmentation. The frequency of spontaneous regressions and the often noted occurrence of metastatic disease many years after removal of the primary lesion have suggested that host factors may play a role in the control of human melanoma. The lack of efficacy of conventional means of therapy has lent impetus to an immunological approach to the treatment of inoperable melanoma. Several uncontrolled studies utilizing intralesional injection of BCG vaccine
M. Mastrangelo, R. S. Bornstein, H. Sulit, D. Chee, J. VV. Yarbro, R. T. Prehn. Immunotherapy of Malignant Melanoma.. Ann Intern Med. 1972;76:877–878. doi: 10.7326/0003-4819-76-5-877_4
Download citation file:
Published: Ann Intern Med. 1972;76(5):877-878.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use